NICE Rejects Keytruda/Inlyta Combo First-Line In RCC
More Mature Evidence Needed Says Draft Guidance
The cost-effectiveness of combination therapies for untreated advanced renal cell carcinoma therapies comes under the spotlight as England's HTA body rejects an immunotherapy/kinase inhibitor combination in draft guidance.
You may also be interested in...
Ipsen is to restart a global Phase III study of palovarotene in an ultra-rare bone disorder after additional analyses of interim data, but a partial clinical hold of the compound's use in patients aged under 14 years of age remains in place.
AveXis/Novartis’s one-time AAV9 vector-based intravenous gene therapy for spinal muscular atrophy, Zolgensma, continues to have beneficial effects up to five years after its administration to babies, and an intrathecal formulation has significant promise in older infants.
Emerging Company Profile: Switzerland’s iOnctura is working on PI3K-delta inhibitors and autotaxin inhibitors that have potential in solid tumors and cancer-associated fibrosis.